Accepted for/Published in: JMIR Dermatology
Date Submitted: Dec 18, 2020
Date Accepted: Apr 14, 2021
Date Submitted to PubMed: Aug 26, 2023
Tetrahydrocannabinol and Skin Cancer: Information on YouTube
ABSTRACT
Background:
Treatment of various skin cancers with topical application of cannabis oil is being utilized by patients as a homeopathic remedy, and has been promoted and popularized on social media, including YouTube. While topical cannabinoids especially tetrahydrocannabinol (THC) may have anti-tumor effects, results from a sparse number of clinical trials and peer-reviewed studies detailing safety and efficacy are still under investigation.
Objective:
We sought to assess the accuracy, quality, and reliability of THC oil and skin cancer information available on YouTube.
Methods:
The 10 most-viewed videos on THC oil and skin cancer were analyzed with the Global Quality Score (GQS), DISCERN Score, and Useful/Misleading criteria based on presentation of erroneous and scientifically unproven information. The videos were also inspected for source, length, and audience likes/dislikes.
Results:
All 10/10 (100%) of videos received a GQS score of 1, corresponding to poor quality of content, and 9/10 (90%) videos received a DISCERN score of 0, indicating poor reliability of information presented. All 10 videos were also found to be Misleading and Not Useful according to established criteria.
Conclusions:
Dermatologists should be aware that the spread of inaccurate information on skin cancer treatment currently exists on popular social media platforms and may lead to detrimental consequences for patients interested in pursuing alternative or homeopathic approaches.
Citation
Request queued. Please wait while the file is being generated. It may take some time.
Copyright
© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.